Pure Global

Safety and Tolerability of IBI355 in Healthy Volunteers - Trial NCT06416787

Access comprehensive clinical trial information for NCT06416787 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06416787
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06416787
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety and Tolerability of IBI355 in Healthy Volunteers
A Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of IBI355 in Healthy Voluteers

Study Focus

Healthy

placebo

Interventional

drug

Sponsor & Location

Innovent Biologics (Suzhou) Co. Ltd.

Beijing, China

Timeline & Enrollment

Phase 1

May 17, 2024

Dec 30, 2025

32 participants

Primary Outcome

Incidence of adverse events and serious adverse events

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics
 of multiple ascending doses of IBI355 in Healthy voluteers. This study also aims to evaluate
 the anti-Drug antibody after multiple ascending doses of IBI355 in Healthy voluteers.

ICD-10 Classifications

Obesity
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmful
Healthy person accompanying sick person
Lifestyle-related condition
Malnutrition

Data Source

ClinicalTrials.gov

NCT06416787

Non-Device Trial